Advanced Cell Technology, Inc. (ACTC) Receives Data and Safety Monitoring Board Authorization to Proceed with Patient Enrollment
Advanced Cell Technology, a leading player in the field of regenerative medicine, today announced it is now authorized to proceed with enrollment and treatment of additional patients in its clinical trial for dry age-related macular degeneration (dry AMD). The authorization, issued by the Data and Safety Monitoring Board (DSMB), allows ACT to continue patient screening and enrollment for the second cohort, who will be injected with 100,000 retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs), as compared with the 50,000-cell dose used in the first cohort. ACT says the DSMB clearance marks a key achievement for…